CO6280574A2 - Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia - Google Patents

Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia

Info

Publication number
CO6280574A2
CO6280574A2 CO09125771A CO09125771A CO6280574A2 CO 6280574 A2 CO6280574 A2 CO 6280574A2 CO 09125771 A CO09125771 A CO 09125771A CO 09125771 A CO09125771 A CO 09125771A CO 6280574 A2 CO6280574 A2 CO 6280574A2
Authority
CO
Colombia
Prior art keywords
methods
vasopresine
anthracicline
antagonists
chemotherapy agents
Prior art date
Application number
CO09125771A
Other languages
English (en)
Inventor
Yongge Liu
Junichi Kambayashi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of CO6280574A2 publication Critical patent/CO6280574A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

La presente invención se refiere a métodos para reducir la cardiotoxicidad y/o para mejorar la supervivencia del tratamiento con agentes de antraciclina que comprenden administrar una cantidad terapéuticamente efectiva de una composición que comprende un compuesto antagonista de vasopresina o una sal farmacéuticamente aceptable del mismo como un ingrediente activo, administrado simultáneamente con o antes de la administración de antraciclina.
CO09125771A 2007-05-15 2009-11-06 Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia CO6280574A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93808907P 2007-05-15 2007-05-15

Publications (1)

Publication Number Publication Date
CO6280574A2 true CO6280574A2 (es) 2011-05-20

Family

ID=40122254

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09125771A CO6280574A2 (es) 2007-05-15 2009-11-06 Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia

Country Status (25)

Country Link
US (1) US8372830B2 (es)
EP (1) EP2146721B1 (es)
KR (1) KR101508797B1 (es)
CN (2) CN101808517A (es)
AR (1) AR066544A1 (es)
AU (1) AU2008254273B2 (es)
BR (1) BRPI0811134A2 (es)
CA (1) CA2685186A1 (es)
CO (1) CO6280574A2 (es)
CY (1) CY1114163T1 (es)
DK (1) DK2146721T3 (es)
ES (1) ES2421639T3 (es)
HK (2) HK1138772A1 (es)
HR (1) HRP20130920T1 (es)
IL (1) IL202094A (es)
MX (1) MX2009012164A (es)
MY (1) MY150682A (es)
NZ (1) NZ581126A (es)
PL (1) PL2146721T3 (es)
PT (1) PT2146721E (es)
RU (1) RU2470643C2 (es)
SI (1) SI2146721T1 (es)
TW (1) TWI428131B (es)
UA (1) UA99914C2 (es)
WO (1) WO2008144269A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2211906A2 (en) * 2007-11-07 2010-08-04 Janssen Pharmaceutica, N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
US20150150843A1 (en) * 2012-05-21 2015-06-04 Randall T. Peterson Cardioprotective compounds, their use with chemotherapy, and methods for identifying them
WO2014062888A1 (en) * 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
US10172911B2 (en) 2013-10-01 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
US11034745B2 (en) 2016-01-04 2021-06-15 Adepthera Llc Superagonist polypeptide analogs of adrenomedullin and intermedin peptide hormones
CN109475604B (zh) * 2016-02-09 2023-04-04 艾得佩索拉公司 长效型clr/ramp激动剂的配量和用途
WO2018226875A2 (en) * 2017-06-07 2018-12-13 University Of Kansas Methods and medicaments for the treatment of renal cell carcinoma
EP3645031A4 (en) 2017-06-30 2021-03-31 Adepthera LLC PEPTIDIC ANALOGUES
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574455A (en) * 1897-01-05 Switch-lock
US5744455A (en) * 1988-01-27 1998-04-28 New York University Reduction of anthracycline-induced cardiotoxicity
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
SI2146721T1 (sl) 2013-10-30
HK1138772A1 (en) 2010-09-03
CA2685186A1 (en) 2008-11-27
EP2146721A4 (en) 2010-08-25
AU2008254273A1 (en) 2008-11-27
RU2470643C2 (ru) 2012-12-27
CN101808517A (zh) 2010-08-18
WO2008144269A3 (en) 2010-01-21
NZ581126A (en) 2012-04-27
TWI428131B (zh) 2014-03-01
MX2009012164A (es) 2009-12-09
US8372830B2 (en) 2013-02-12
KR20100019439A (ko) 2010-02-18
TW200916104A (en) 2009-04-16
MY150682A (en) 2014-02-28
EP2146721A2 (en) 2010-01-27
IL202094A (en) 2015-06-30
UA99914C2 (ru) 2012-10-25
WO2008144269A2 (en) 2008-11-27
BRPI0811134A2 (pt) 2014-09-30
PL2146721T3 (pl) 2013-12-31
PT2146721E (pt) 2013-07-18
IL202094A0 (en) 2010-06-16
EP2146721B1 (en) 2013-07-10
AU2008254273B2 (en) 2013-03-28
ES2421639T3 (es) 2013-09-04
CY1114163T1 (el) 2016-08-31
CN103550233A (zh) 2014-02-05
AR066544A1 (es) 2009-08-26
HRP20130920T1 (hr) 2013-11-08
KR101508797B1 (ko) 2015-04-06
DK2146721T3 (da) 2013-07-22
RU2009146376A (ru) 2011-06-20
HK1176318A1 (en) 2013-07-26
US20100249104A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
CR20140086A (es) Tratamientos de combinación para hepatitis c
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
PE20120713A1 (es) Composiciones sublinguales de dexmedetomidina y metodos para su uso
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
BR112015014433A2 (pt) compostos tricíclicos
MX2009005798A (es) Recuperacion de apoplejia.
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
PE20211738A1 (es) Formulacion basada en ciclodextrina de un inhibidor de bcl-2
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
GT201000064A (es) Formulaciones galénicas de alisquireno
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
AR068608A1 (es) Neramexano para el tratamiento de nistagmo
WO2009137436A3 (en) Peptide conjugates

Legal Events

Date Code Title Description
FC Application refused